Opportunity
Simpler Grants.gov #RFA-CA-25-033
NCI Solicits Research Applications for Glioblastoma Therapeutics Network
Buyer
National Cancer Institute (NCI)
Posted
September 17, 2025
Respond By
May 27, 2026
Identifier
RFA-CA-25-033
NAICS
541714, 541715
The National Cancer Institute (NCI), part of the National Institutes of Health, is seeking applications for the Glioblastoma Therapeutics Network (GTN) to advance research and development of new therapies for adult glioblastoma (GBM). - Government Buyer: - National Cancer Institute (NCI), National Institutes of Health - Products/Services Requested: - Research and development services focused on novel or repurposed therapeutic agents for adult glioblastoma - Agents must be able to cross the blood brain barrier and be suitable for clinical testing - Scope includes late pre-clinical development, IND-enabling studies, and early (Phase 0/1) clinical trials - Eligible Applicants: - Open to government entities, nonprofits, businesses, educational institutions, and tribal organizations - Unique/Notable Requirements: - Emphasis on collaborative teams capable of moving therapies from pre-clinical to clinical stages - Both novel compounds and repurposed drugs (approved for other indications) are eligible if appropriate preclinical studies are conducted - No specific OEMs or vendors are named, as this is a research grant opportunity - Place of Performance: - National Cancer Institute (NCI)
Description
The National Cancer Institute (NCI) is soliciting applications for research on novel therapies for adult glioblastoma (GBM) through this Notice of Funding Opportunity (NOFO). The goal is to improve treatment by developing novel effective agents that can cross the blood brain barrier and testing them clinically. A collaborative GBM Therapeutics Network (GTN) will be established to drive therapeutic agents from pre-clinical development through early clinical studies. Eligible therapeutic agents include novel agents or repurposed agents approved for other indications following appropriate preclinical studies. This NOFO spans late pre-clinical through early Phase 0/1 clinical studies to address a gap in GBM drug development.